Research ArticleAccepted Articles
Open Access
Safety of guselkumab with and without prior TNF-α inhibitor treatment: Pooled results across four studies in patients with psoriatic arthritis
Proton Rahman, Wolf-Henning Boehncke, Philip J. Mease, Alice B. Gottlieb, Iain B. McInnes, May Shawi, Yanli Wang, Shihong Sheng, Alexa P. Kollmeier, Elke Theander, Jenny Yu, Evan Leibowitz, A. Marilise Marrache and Laura C. Coates
The Journal of Rheumatology January 2023, jrheum.220928; DOI: https://doi.org/10.3899/jrheum.220928
Proton Rahman
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
Wolf-Henning Boehncke
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
Philip J. Mease
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
Alice B. Gottlieb
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
Iain B. McInnes
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
May Shawi
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
Yanli Wang
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
Shihong Sheng
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
Alexa P. Kollmeier
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
Elke Theander
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
Jenny Yu
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
Evan Leibowitz
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
A. Marilise Marrache
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
Laura C. Coates
Craig L Dobbin Genetics Research Centre, Memorial University of Newfoundland, St. John's, NL, Canada. Geneva University Hospitals, Geneva, Switzerland. Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA. Icahn School of Medicine at Mount Sinai, New York, USA. University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK. Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA. Janssen Research & Development, LLC, Spring House, PA, USA. Immunology, Janssen Research & Development, LLC, San Diego, CA, USA. Janssen Scientific Affairs, LLC, Solna, Sweden. Janssen Scientific Affairs, LLC, Horsham, PA, USA. Medical Affairs, Janssen Inc., Toronto, Canada. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Funding: The Phase 2 Guselkumab in Psoriatic Arthritis, DISCOVER-1, DISCOVER-2, and COSMOS studies were funded by Janssen Research & Development, LLC. Address correspondence to: Dr. Proton Rahman, 154 LeMarchant Road, St. Clare's Mercy Hospital, St. John's Newfoundland, Canada A1C 5B8. Email: prahman@mun.ca. Conflicts of Interest: PR: received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB; research grants from Janssen and Novartis. WHB: speaker for AbbVie, Almirall, Janssen, Leo and UCB; advisory board participation for AbbVie, Almirall, BMS, Janssen, Leo, Lilly, Novartis, and UCB. PJM: received research support, consulting fees, and/or speaker bureau support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB. ABG: Honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai. IBM: consultant fees from Astra Zeneca, AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Cabaletta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB; grant/research support from Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB; shareholder of Causeway Therapeutics, Evelo Compugen.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 50, Issue 3
1 Mar 2023
Accepted manuscript
Safety of guselkumab with and without prior TNF-α inhibitor treatment: Pooled results across four studies in patients with psoriatic arthritis
Proton Rahman, Wolf-Henning Boehncke, Philip J. Mease, Alice B. Gottlieb, Iain B. McInnes, May Shawi, Yanli Wang, Shihong Sheng, Alexa P. Kollmeier, Elke Theander, Jenny Yu, Evan Leibowitz, A. Marilise Marrache, Laura C. Coates
The Journal of Rheumatology Jan 2023, jrheum.220928; DOI: 10.3899/jrheum.220928
Accepted manuscript
Safety of guselkumab with and without prior TNF-α inhibitor treatment: Pooled results across four studies in patients with psoriatic arthritis
Proton Rahman, Wolf-Henning Boehncke, Philip J. Mease, Alice B. Gottlieb, Iain B. McInnes, May Shawi, Yanli Wang, Shihong Sheng, Alexa P. Kollmeier, Elke Theander, Jenny Yu, Evan Leibowitz, A. Marilise Marrache, Laura C. Coates
The Journal of Rheumatology Jan 2023, jrheum.220928; DOI: 10.3899/jrheum.220928
